Cadrenal says Phase 2 trial of CAD-1005 cuts thrombotic events by more than 25% in HIT - CVKD News | RalliesCadrenal says Phase 2 trial of CAD-1005 cuts thrombotic events by more than 25% in HIT
C
CVKD• Phase 2 results for CAD-1005 in HIT
- Cadrenal reported Phase 2 data for CAD-1005 in HIT showing an absolute reduction of more than 25% in thrombotic events.
- Thrombotic events fell to 50% on CAD-1005 versus more than 75% on placebo; the trial was not powered for statistical significance.
- Safety readout showed no serious adverse events attributed to CAD-1005, no major bleeding in SRA+ patients, no deaths.
- Results support advancing the program toward a pivotal Phase 3 registration trial.
- CAD-1005 holds FDA Orphan Drug and Fast Track designations, with EMA Orphan Drug status.
